Herbal Medicine

Green Tea and Rooibos Tea Inhibit ACE Activity

By Shari Henson | American Botanical Council - Vol. 11, No. 2. Summer, 2010

Data from a well-designed Swedish study indicate that green tea and Roiboos tea—but not black tea—can significantly inhibit Angiotensin Converting Enzyme, and potentially lower blood pressure. An HerbClip from the American Botanical Council.

New Study Corroborates Ginger’s Benefit in Quelling Morning Sickness Nausea

By Tori Hudson, ND | Contributing Writer - Vol. 11, No. 1. Spring , 2010
Ginger is widely available, safe, inexpensive, and, it turns out, one of the best possible remedies for pregnancy-associated nausea. A new clinical trial involving nearly 70 women, shows that at a dose of 250 mg, four times daily, ginger is highly effective in controlling nausea and reducing vomiting.

Hibiscus Hems Hypertension

By Tori Hudson, ND | Contributing Writer - Vol. 10, No. 4. Winter, 2009

Hibiscus, a popular tea herb in many parts of the world, can markedly lower systolic blood pressure in type II diabetic people with mild hypertension, according to a recent clinical trial. On the other hand, black tea tends to increase systolic pressure.

Elderberry Extract Quells Influenza Symptoms

By Administrator - Vol. 10, No. 4. Winter, 2009

An extract of Elderberry (Sambucus) proved effective in reducing symptoms associated with human influenza in a new placebo-controlled clinical trial.

Intensive Essential Oil Therapy: Effective Treatment for Common Acute Infections

By Corinne Adrion-Israelsen | Contributing Writer - Vol. 7, No. 4. Winter, 2006

In the US, most people use aromatic essential oils for relaxation and other forms of aromatherapy. In France, they have a long history of internal use for the prevention and treatment of common infections. Corinne Andrion-Israelsen, who trained in the French tradition, explores the history and clinical application of plant essential oils.

Teas, Tinctures, and Extracts: Understanding the Forms of Herbal Medicine

By Janet Gulland | Staff Writer - Vol. 1, No. 1. October, 2000

It's not just what herbs you take but how you take them. The form in which an herb is taken has a big impact on its clinical effects. Teas, tinctures, decoctions, standardized extracts and pills containing the same herb may have somewhat different effects. Tieraona Low Dog, MD, a physician and herbalist, defines the different forms of herbal therapy and their merits and faults.

Herb Industry Grows Increasingly Quality-Conscious

By Erik L. Goldman | Editor in Chief - Vol. 1, No. 1. October, 2000

As use of herbal medicines continues to grow, supplement industry trade groups are implementing a number of self-regulation systems to try and improve the quality and reliability of botanical medicine products.

Herb Side Effects Need Better Tracking: Inadequate Surveillance Leaves Data Gap

By Jim Rowe | Contributing Writer - Vol. 1, No. 1. October, 2000

While herbal medicines are generally considered to be quite safe, there are currently no laws mandating physicians to report adverse events associated with herbs to federal authorities. Similarly, there are no laws requiring the FDA to investigate reported incidents. Without better national reporting and follow-up systems, it is difficult to gauge the true safety of common herbal medicines.

Indie Labs Play Supplement Rating Game: New Product Evaluation Tools

By Jim Rowe | Contributing Writer - Vol. 1, No. 1. October, 2000

Independent laboratories and private companies are jumping into the dietary supplement rating game, hoping to bridge what many see as a gap in government oversight.

NIDDK Will Test Milk Thistle in Hepatitis C: Patients Say, "Thistle Do It"

By Erik L. Goldman | Editor in Chief - Vol. 1, No. 2. December, 2000

Silymarin, a mixture of compounds derived from Milk Thistle, is a popular herbal medicine for hepatitis C, cirrhosis, and other liver disorders. Clinical trials show that these compounds have anti-inflammatory and antioxidant effects that can slow the progression of these diseases. Researchers at the National Institutes of Health have begun a large-scale trial of silymarin in conjunction with conventional drugs for treatment of hepatitis C.